Health Condition 1: null- ASA 1,ASA 2 patients were included in the study
Conditions
Interventions
Intervention1: Group C: Patients who received 30 ml of 0.5% Levobupivacaine + 50 microgram (0.5 ml)clonidine
Control Intervention1: Group L: Patients who received 30 ml of 0.5% Levobuivacaine +0.5 ml
Sponsors
Dr KF Kammar
Eligibility
Inclusion criteria
Inclusion criteria: ASA 1 and ASA 2 patients scheduled for elective upper limb surgeries
Exclusion criteria
Exclusion criteria: patient refusal Allergy to trial drugs Clavicular fracture Skin infection at needle insertion site Morbid obesity Patients with coagulopathy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Duration of postoperative analgesiaTimepoint: Duration of postoperative analgesia | — |
Secondary
| Measure | Time frame |
|---|---|
| Duration of motor blockTimepoint: Time interval between the end of drug administration and the complete recovery of motor function of upper limb;Duration of sensory blockTimepoint: Time interval between onset of sensory anaesthesia and the complete resolution of anaesthesia on all nerves;Onset of Motor BlockTimepoint: Time taken from completion of injection of study drug to the maximum motor block attained;Onset of sensory blockadeTimepoint: Time taken from completion of injection of study drug to the first loss of pin prick sensation in C5-T1 dermatome using a blunt needle;Quality of blockTimepoint: Grade 4: No complaint from patient Grade 3: Minor complaint with no need of supplemental analgesics Grade 2: Complaint that required supplemental analgesics Grade 1:Patient given general anaesthesia | — |
Countries
India
Contacts
Public ContactDr Elizabeth Wilson
Rajiv Gandhi University Of Health Sciences
Outcome results
None listed